In agreement with this prediction, the rotenone derivative deguelin suppressed tumour growth in a prostate cancer mouse model lacking both PTEN and Trp53. 72 Overall, these data provide evidence that targeting oxidative phosphorylation might be an effective therapeutic approach for prostate cancer. This evidence concerns the gene PTEN and neoplasm.